GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Cash Payments

SCYNEXIS (LTS:0L49) Cash Payments


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.